Management of translocation carcinomas of the kidney

被引:3
作者
Ged, Yasser [1 ]
Feinaj, Ardit [1 ]
Baraban, Ezra [2 ]
Singla, Nirmish [3 ]
机构
[1] Johns Hopkins Med Inst, Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, 201 N Broadway Fl 5, Baltimore, MD 21287 USA
[2] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21231 USA
[3] Johns Hopkins Med Inst, James Buchanan Brady Urol Inst, Dept Urol, Baltimore, MD USA
关键词
Renal cell carcinoma (RCC); translocation RCC; genomics; immunotherapy; targeted therapy; RENAL-CELL CARCINOMA; MEMBRANE ANTIGEN PSMA; GENE FUSION; CANCER; EXPRESSION; PART; CLASSIFICATION; THERAPY; GROWTH; TUMORS;
D O I
10.21037/tcr-24-60
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Microphthalmia-associated transcription factor family translocation renal cell carcinoma (MiT-tRCC) stands out as a rare subtype of kidney cancer with distinct biological features compared to other kidney cancer subtypes. It encompasses TFE3-rearranged RCC (also known as Xp11 translocation RCC) and TFE-rearranged translocations RCC, although multiple new fusion partners were identified. Traditionally thought to primarily affect children and young adults, more cases of MiT-tRCC are being identified in adults. It was first officially recognized in the 2004 World Health Organization (WHO) renal tumor classification and recently TFE3 (Xp11) rearrangement and TFEB alterations were included in the WHO 2022 "molecularly defined renal carcinomas" as a distinct group. This subtype is distinguished by gene fusions involving the MiT family of transcription factors. Recent strides in diagnostic and molecular sequencing assays have significantly enhanced our comprehension of these tumors, uncovering novel and distinct molecular features. The discovery of novel immune-checkpoint inhibitors and anti-angiogenic targeted therapies has notably broadened the therapeutic options for clear cell RCC. These advancements have prompted the consideration and study of these innovative therapies in translocation RCC. In this review, we offer an overview of translocation RCC and delve into the current strides in the management of this distinctive disease, highlighting the integration of recent breakthroughs in therapeutic approaches.
引用
收藏
页码:6438 / 6447
页数:10
相关论文
共 62 条
[21]   Characterization of a 3;6 translocation associated with renal cell carcinoma [J].
Foster, Rebecca E. ;
Abdulrahman, Mahera ;
Morris, Mark R. ;
Prigmore, Elena ;
Gribble, Susan ;
Ng, Beeling ;
Gentle, Dean ;
Ready, Steven ;
Weston, Phil M. T. ;
Wiesener, Michael S. ;
Kishida, Takeshi ;
Yao, Masahiro ;
Davison, Val ;
Luis Barbero, Jose ;
Chu, Carol ;
Carter, Nigel P. ;
Latif, Farida ;
Maher, Eamonn R. .
GENES CHROMOSOMES & CANCER, 2007, 46 (04) :311-317
[22]   MiT family translocation renal cell carcinomas: A 15th anniversary update [J].
Gandhi, Jatin S. ;
Malik, Faizan ;
Amin, Mahul B. ;
Argani, Pedram ;
Bahrami, Armita .
HISTOLOGY AND HISTOPATHOLOGY, 2020, 35 (02) :125-136
[23]  
Ged Y., 2023, 2023 INT KIDN CANC S
[24]   Novel emerging biomarkers to immunotherapy in kidney cancer [J].
Ged, Yasser ;
Voss, Martin H. .
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
[25]   Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer [J].
Ghosh, A ;
Heston, WDW .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2004, 91 (03) :528-539
[26]   Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers [J].
Goodman, Aaron M. ;
Kato, Shumei ;
Bazhenova, Lyudmila ;
Patel, Sandip P. ;
Frampton, Garrett M. ;
Miller, Vincent ;
Stephens, Philip J. ;
Daniels, Gregory A. ;
Kurzrock, Razelle .
MOLECULAR CANCER THERAPEUTICS, 2017, 16 (11) :2598-2608
[27]  
Green WM, 2013, AM J SURG PATHOL, V37, P1150, DOI 10.1097/PAS.0b013e31828a69ae
[28]   Clinical research for rare disease: Opportunities, challenges, and solutions [J].
Griggs, Robert C. ;
Batshaw, Mark ;
Dunkle, Mary ;
Gopal-Srivastava, Rashmi ;
Kaye, Edward ;
Krischer, Jeffrey ;
Nguyen, Tan ;
Paulus, Kathleen ;
Merkel, Peter A. .
MOLECULAR GENETICS AND METABOLISM, 2009, 96 (01) :20-26
[29]   Molecular-genetic analysis is essential for accurate classification of renal carcinoma resembling Xp11.2 translocation carcinoma [J].
Hayes, Malcolm ;
Peckova, Kvetoslava ;
Martinek, Petr ;
Hora, Milan ;
Kalusova, Kristyna ;
Straka, Lubomir ;
Daum, Ondrej ;
Kokoskova, Bohuslava ;
Rotterova, Pavla ;
Pivovarcikova, Kristyna ;
Branzovsky, Jindrich ;
Dubova, Magdalena ;
Vesela, Pavla ;
Michal, Michal ;
Hes, Ondrej .
VIRCHOWS ARCHIV, 2015, 466 (03) :313-322
[30]  
Hsieh JJ, 2017, NAT REV DIS PRIMERS, V3, DOI [10.1038/nrdp.2017.10, 10.1038/nrdp.2017.9]